

Lao pharmaceutical company BioSpring announces acquisition agreement with cancer drug company Sailin Biopharma

BioSpring Completes Targeted Therapy Product Line

VIENTIANE, LAOS, July 27, 2022 /EINPresswire.com/ -- BioSpring ("BioSpring Group.LTD" "BioSpring Group") announces Acquisition of Laos Anticancer Drug Company Sailin biopharma.

The acquisition is to strengthen BIOSspring's technological advantages and manufacturing capacity in the field of anticancer drugs. SAILIN's product line is mainly focused on the field of oral targeted therapy.



The acquisition is expected to be

completed before the end of this year. After the acquisition and integration, BioSpring will not continue to operate the SAILIN brand, but will adopt a single product system.

"

This acquisition helps us accelerate our planned product pipeline: Targeted Therapy, Antiviral Medications, Consumer Brand."

Samuel, founder and CEO of BioSpring Through this acquisition, BioSpring has obtained mature formulation processes and manufacturing capacity for at least 12 anticancer drugs.And the necessary development and manufacturing conditions for the continuous development of new products in the field of anticancer drugs.

Samuel, founder and CEO of BioSpring, said: "This acquisition helps us accelerate our planned product pipeline: Targeted Therapy, Antiviral Medications, Consumer Brand." "We hope that by this time next year, all three product lines will form a certain competitive group."

DBioSpring will acquire all formulations, processes and equipment for SAILIN's anticancer drug product line.

BioSpring's acquisition of SAILIN includes its brand, but BioSpring does not operate its brand.

□All acquisitions are expected to be completed by the end of this year.

About BioSpring

Founded in 2022 at the Vientiane Saiseta Comprehensive Development Zone in Laos, BioSpring is the country's fastest growing generic drug manufacturing company and the country's first pharmaceutical



company targeting the international market, serving Asia, Africa, Europe and Latin America Americas and many other countries and regions.

Visit:<u>www.biospring.ltd</u> to know more information.

About Sailin Biopharma

Sailin biopharmaceutical (Laos) co., LTD., and the construction in 2019, is currently the largest and the most technologically advanced Laos anticancer and antiviral drugs production enterprise joint pharmaceutical group co., LTD., a subsidiary of the country's fastest growing large pharmaceutical companies.

Sailin pharmaceutical is a pharmaceutical enterprise management practices, in vientiane Rosetta park covers an area of 60 mu, raw material production and preparation production is equal to one, the company has more than 152 employees.

Visit: <u>www.sailin-bio.com/en/</u> to know more information.

Forward-Looking Statements

To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company. Source: BioSpring Group.LTD

Spencer RxLibra pharmaceutical Sole Co.,Ltd 20 54 177 436 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/583208309

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 Newsmatics Inc. All Right Reserved.